Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 18 | 2023 | 2096 | 3.290 |
Why?
|
| Heart Transplantation | 7 | 2021 | 714 | 2.140 |
Why?
|
| Heart-Assist Devices | 6 | 2022 | 561 | 2.110 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 341 | 1.000 |
Why?
|
| Cardiology | 2 | 2020 | 286 | 0.960 |
Why?
|
| Patient Selection | 2 | 2020 | 685 | 0.950 |
Why?
|
| Stroke Volume | 5 | 2023 | 598 | 0.900 |
Why?
|
| Hospice Care | 2 | 2023 | 204 | 0.800 |
Why?
|
| Registries | 5 | 2019 | 2205 | 0.760 |
Why?
|
| Defibrillators, Implantable | 2 | 2016 | 318 | 0.730 |
Why?
|
| Medicare | 3 | 2023 | 802 | 0.730 |
Why?
|
| Cardiovascular Agents | 1 | 2022 | 157 | 0.680 |
Why?
|
| Home Care Services | 1 | 2023 | 241 | 0.670 |
Why?
|
| Waiting Lists | 2 | 2019 | 245 | 0.640 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2022 | 374 | 0.640 |
Why?
|
| BK Virus | 1 | 2019 | 16 | 0.630 |
Why?
|
| Population Health | 1 | 2020 | 45 | 0.620 |
Why?
|
| Immunocompromised Host | 2 | 2020 | 201 | 0.590 |
Why?
|
| Patient Advocacy | 1 | 2019 | 74 | 0.590 |
Why?
|
| Viremia | 1 | 2019 | 154 | 0.580 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2016 | 46 | 0.570 |
Why?
|
| Renal Insufficiency | 1 | 2019 | 170 | 0.530 |
Why?
|
| Triage | 1 | 2020 | 250 | 0.530 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2018 | 83 | 0.530 |
Why?
|
| Organizational Objectives | 1 | 2017 | 65 | 0.530 |
Why?
|
| Betacoronavirus | 1 | 2020 | 277 | 0.520 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 99 | 0.520 |
Why?
|
| Health Policy | 1 | 2020 | 385 | 0.520 |
Why?
|
| Heart Diseases | 1 | 2020 | 337 | 0.510 |
Why?
|
| Pacemaker, Artificial | 1 | 2018 | 121 | 0.490 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2016 | 12 | 0.490 |
Why?
|
| Cardiovascular System | 1 | 2017 | 137 | 0.480 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 948 | 0.470 |
Why?
|
| Electric Countershock | 1 | 2016 | 115 | 0.470 |
Why?
|
| Mentors | 1 | 2017 | 213 | 0.460 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 374 | 0.450 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 449 | 0.450 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 370 | 0.450 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2016 | 193 | 0.440 |
Why?
|
| Mentoring | 1 | 2017 | 150 | 0.440 |
Why?
|
| Health Services Research | 1 | 2017 | 401 | 0.440 |
Why?
|
| Primary Prevention | 1 | 2016 | 202 | 0.430 |
Why?
|
| Quality Improvement | 2 | 2020 | 1241 | 0.380 |
Why?
|
| Medication Adherence | 1 | 2016 | 510 | 0.360 |
Why?
|
| Biomedical Research | 1 | 2017 | 684 | 0.340 |
Why?
|
| Humans | 28 | 2023 | 141284 | 0.330 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 501 | 0.320 |
Why?
|
| United States | 9 | 2023 | 15298 | 0.320 |
Why?
|
| Insurance, Health | 3 | 2021 | 296 | 0.310 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2019 | 99 | 0.270 |
Why?
|
| Aged, 80 and over | 5 | 2023 | 7948 | 0.260 |
Why?
|
| Female | 15 | 2023 | 75814 | 0.230 |
Why?
|
| Patient Readmission | 2 | 2022 | 698 | 0.210 |
Why?
|
| Treatment Outcome | 6 | 2020 | 11216 | 0.200 |
Why?
|
| Aged | 9 | 2023 | 24836 | 0.190 |
Why?
|
| Male | 13 | 2023 | 70140 | 0.190 |
Why?
|
| Risk Factors | 3 | 2023 | 10490 | 0.180 |
Why?
|
| Community-Based Participatory Research | 1 | 2022 | 162 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 1336 | 0.170 |
Why?
|
| Insurance Carriers | 1 | 2021 | 12 | 0.170 |
Why?
|
| Logistic Models | 2 | 2016 | 2098 | 0.170 |
Why?
|
| Pericarditis | 1 | 2020 | 11 | 0.160 |
Why?
|
| Aftercare | 1 | 2022 | 218 | 0.160 |
Why?
|
| Cryptococcus neoformans | 1 | 2020 | 21 | 0.160 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 2904 | 0.160 |
Why?
|
| Cryptococcosis | 1 | 2020 | 31 | 0.160 |
Why?
|
| Cardiologists | 1 | 2020 | 46 | 0.160 |
Why?
|
| Patient Participation | 2 | 2021 | 427 | 0.160 |
Why?
|
| Hospitalization | 2 | 2023 | 2264 | 0.160 |
Why?
|
| Hospices | 1 | 2021 | 88 | 0.160 |
Why?
|
| Retrospective Studies | 5 | 2023 | 16447 | 0.150 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 5222 | 0.150 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 269 | 0.150 |
Why?
|
| Coronary Artery Bypass | 1 | 2021 | 251 | 0.150 |
Why?
|
| Cardiotonic Agents | 1 | 2019 | 95 | 0.150 |
Why?
|
| Risk Assessment | 2 | 2020 | 3522 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 451 | 0.140 |
Why?
|
| Adult | 8 | 2021 | 39319 | 0.140 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 85 | 0.130 |
Why?
|
| Community Health Services | 1 | 2019 | 232 | 0.130 |
Why?
|
| Viral Load | 1 | 2019 | 507 | 0.130 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2017 | 45 | 0.130 |
Why?
|
| Long-Term Care | 1 | 2018 | 110 | 0.130 |
Why?
|
| Professional Competence | 1 | 2017 | 96 | 0.130 |
Why?
|
| Time Factors | 3 | 2016 | 6951 | 0.130 |
Why?
|
| Stakeholder Participation | 1 | 2017 | 80 | 0.120 |
Why?
|
| Patient Safety | 1 | 2020 | 335 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2018 | 5809 | 0.120 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 190 | 0.120 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 15 | 0.120 |
Why?
|
| Patient Discharge | 1 | 2022 | 915 | 0.120 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2016 | 55 | 0.120 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2021 | 489 | 0.120 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 674 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1491 | 0.110 |
Why?
|
| Career Choice | 1 | 2017 | 233 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 526 | 0.110 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 163 | 0.110 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 282 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 197 | 0.110 |
Why?
|
| Physicians | 1 | 2023 | 930 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 716 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 612 | 0.110 |
Why?
|
| Propensity Score | 1 | 2016 | 337 | 0.110 |
Why?
|
| Caregivers | 1 | 2022 | 940 | 0.100 |
Why?
|
| Postoperative Care | 1 | 2016 | 280 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 910 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2019 | 748 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2017 | 417 | 0.100 |
Why?
|
| Dyspnea | 1 | 2015 | 258 | 0.100 |
Why?
|
| Survival Rate | 1 | 2018 | 1979 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1243 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 1268 | 0.100 |
Why?
|
| Medicaid | 1 | 2017 | 450 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2016 | 1322 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 539 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 1178 | 0.090 |
Why?
|
| Pandemics | 1 | 2020 | 1655 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1505 | 0.080 |
Why?
|
| Curriculum | 1 | 2017 | 1035 | 0.080 |
Why?
|
| Age Factors | 1 | 2018 | 3295 | 0.080 |
Why?
|
| Middle Aged | 6 | 2021 | 34658 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2019 | 2831 | 0.070 |
Why?
|
| Exercise Test | 2 | 2021 | 620 | 0.060 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 5948 | 0.050 |
Why?
|
| Pericardiocentesis | 1 | 2020 | 9 | 0.040 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 88 | 0.040 |
Why?
|
| Fluconazole | 1 | 2020 | 21 | 0.040 |
Why?
|
| Health Services Misuse | 1 | 2020 | 35 | 0.040 |
Why?
|
| Focus Groups | 1 | 2023 | 565 | 0.040 |
Why?
|
| Income | 1 | 2020 | 198 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2020 | 144 | 0.040 |
Why?
|
| Echocardiography | 1 | 2020 | 647 | 0.030 |
Why?
|
| Organ Transplantation | 1 | 2020 | 252 | 0.030 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 275 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 433 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2017 | 135 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 579 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2015 | 104 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2017 | 239 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1807 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 855 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1610 | 0.030 |
Why?
|
| Palliative Care | 1 | 2021 | 820 | 0.030 |
Why?
|
| Decision Making | 1 | 2021 | 949 | 0.020 |
Why?
|
| Acute Disease | 1 | 2015 | 1005 | 0.020 |
Why?
|
| Young Adult | 2 | 2021 | 13727 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2015 | 696 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 1037 | 0.020 |
Why?
|
| Adolescent | 2 | 2021 | 22116 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 4080 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 4180 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2015 | 7805 | 0.010 |
Why?
|